Detalhe da pesquisa
1.
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Ann Hematol
; 103(2): 437-442, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38060001
2.
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19.
Am J Hematol
; 97(12): E470-E473, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111658
3.
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.
Blood
; 123(15): 2416-9, 2014 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24553179
4.
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Blood
; 123(10): 1544-51, 2014 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24366362
5.
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Blood
; 124(7): 1062-9, 2014 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24986690
6.
LNK mutations in familial myeloproliferative neoplasms.
Blood
; 128(1): 144-5, 2016 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27216218
7.
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.
NEJM Evid
; 2(6): EVIDoa2200335, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38320126
8.
The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
Blood Adv
; 6(4): 1162-1174, 2022 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34933330
9.
Universal Newborn Screening for Congenital Cytomegalovirus Infection - From Infant to Maternal Infection: A Prospective Multicenter Study.
Front Pediatr
; 10: 909646, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35874574
10.
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
Lancet Haematol
; 8(3): e175-e184, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476571
11.
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
Blood Cancer J
; 11(2): 21, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33563901
12.
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
Leukemia
; 35(2): 485-493, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414483
13.
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia.
Haematologica
; 100(11): e443-5, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26250575
14.
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.
Ann Hematol
; 94(11): 1927-8, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26202607
15.
Repurposing of Plasminogen: An Orphan Medicinal Product Suitable for SARS-CoV-2 Inhalable Therapeutics.
Pharmaceuticals (Basel)
; 13(12)2020 Nov 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33260813
16.
A novel germline JAK2 mutation in familial myeloproliferative neoplasms.
Am J Hematol
; 89(1): 117-8, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24142793
17.
Straightforward recursive partitioning model for discarding insoluble compounds in the drug discovery process.
J Med Chem
; 51(10): 2891-7, 2008 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-18419111
18.
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.
Blood Cancer J
; 8(3): 25, 2018 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29535299
19.
Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms.
Oncotarget
; 8(20): 33416-33421, 2017 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28422716
20.
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria.
Oncotarget
; 8(60): 101735-101744, 2017 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29254200